Quintet Private Bank Europe S.A. Purchases 857 Shares of Eli Lilly and Company (NYSE:LLY)

Quintet Private Bank Europe S.A. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 37,702 shares of the company’s stock after acquiring an additional 857 shares during the quarter. Eli Lilly and Company makes up approximately 1.8% of Quintet Private Bank Europe S.A.’s portfolio, making the stock its 18th largest position. Quintet Private Bank Europe S.A.’s holdings in Eli Lilly and Company were worth $31,138,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. RMR Wealth Builders increased its position in Eli Lilly and Company by 4.9% in the 1st quarter. RMR Wealth Builders now owns 4,917 shares of the company’s stock worth $4,061,000 after buying an additional 231 shares during the period. NorthCrest Asset Manangement LLC grew its stake in shares of Eli Lilly and Company by 8.5% in the first quarter. NorthCrest Asset Manangement LLC now owns 19,667 shares of the company’s stock worth $16,243,000 after acquiring an additional 1,541 shares during the last quarter. Liberty Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 5.6% in the first quarter. Liberty Capital Management Inc. now owns 2,375 shares of the company’s stock worth $1,962,000 after acquiring an additional 125 shares during the last quarter. Legacy Trust grew its stake in shares of Eli Lilly and Company by 1.7% in the first quarter. Legacy Trust now owns 1,157 shares of the company’s stock worth $956,000 after acquiring an additional 19 shares during the last quarter. Finally, Rockland Trust Co. grew its stake in shares of Eli Lilly and Company by 17.9% in the first quarter. Rockland Trust Co. now owns 13,760 shares of the company’s stock worth $11,365,000 after acquiring an additional 2,089 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. HSBC lowered shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Finally, Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $811.62 on Friday. The stock’s fifty day simple moving average is $773.53 and its 200 day simple moving average is $801.30. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $769.20 billion, a price-to-earnings ratio of 69.31, a P/E/G ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 earnings per share. The business’s revenue was up 45.2% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.